Is this email not displaying correctly? View in your browser.
Send to a colleague
Anti-CGRP therapies, erenumab, fremanezumab and galcanezumab, are being approved for use in a growing number of countries worldwide with varying arrangements for reimbursement. Eptinezumab and the gepants, ubrogepant, atogepant and rimegepant, are being assessed by regulatory agencies or are in clinical development.
Use our new expert guide to find out about the regulatory status and approved indications for anti-CGRP therapies around the world. We will provide regular updates to keep you informed of any changes in your region.

Read more »

Becoming a member is easy
Members have free open access simply by registering online.
Join today >
Educational Partners and Supporters (others pending)
You are receiving this email because you have subscribed to receive updates from CGRP Forum.
Should you wish to cancel your subscription, please click here to unsubscribe.